Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 15, 2016. The filing serves to announce the company's financial results for the second quarter ended June 30, 2016. The full details of these results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not provide specific comparative data or material changes versus the prior period. It solely references the issuance of the Q2 2016 results press release.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name is Imprimis Pharmaceuticals, Inc., as the request metadata incorrectly listed "Harrow, Inc."
- Locate and review Exhibit 99.1 (the press release dated August 15, 2016) to obtain actual financial figures for the quarter ended June 30, 2016.
- Confirm that the financial data in the press release is not incorporated by reference into other SEC filings unless explicitly stated.